loader
Please Wait
Applying Filters...

Annual Sales of Remodulin reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

Menu
$ API Ref.Price (USD/KG) : 360,846Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 1Nebulized Tyvaso

02 5Remodulin

03 4Tyvaso

04 1Tyvaso DPI

PharmaCompass

01

Brand Name : Remodulin

Treprostinil Sodium

arrow
FNCE 2024
Not Confirmed

02

Brand Name : Tyvaso

Treprostinil

arrow
FNCE 2024
Not Confirmed

03

Brand Name : Tyvaso

Treprostinil

arrow
FNCE 2024
Not Confirmed

04

Brand Name : Remodulin

Treprostinil Sodium

arrow
FNCE 2024
Not Confirmed

05

Brand Name : Tyvaso

Treprostinil

arrow
FNCE 2024
Not Confirmed

06

Brand Name : Remodulin

Treprostinil Sodium

arrow
FNCE 2024
Not Confirmed

07

Brand Name : Remodulin

Treprostinil Sodium

arrow
FNCE 2024
Not Confirmed

08

Brand Name : Tyvaso

Treprostinil

arrow
FNCE 2024
Not Confirmed

09

Brand Name : Remodulin

Treprostinil Sodium

arrow
FNCE 2024
Not Confirmed

10

Brand Name : Nebulized Tyvaso

Treprostinil

arrow
FNCE 2024
Not Confirmed

Brand Name : Nebulized Tyvaso

arrow
FNCE 2024
Not Confirmed

Treprostinil

Main Therapeutic Indication : Cardiology/Vascular Diseases

Currency : USD

2023 Revenue in Millions : 503

2022 Revenue in Millions : 715

Growth (%) : -30

blank